HomeCancerLeukemia Correction: A novel lncRNA SNHG29 regulates EP300- associated histone acetylation modification and inhibits FLT3-ITD AML growth – Nature.com Leukemia July 23, 2024 98 0 Purposeful Precision Drugs: The New Precision Oncology? August 6, 2026 The Story of Immune Checkpoint Inhibitors and Immunotherapy July 21, 2026 Reflections on Progress at ASCO 2026 June 23, 2026 NCI’s Message and High Priorities June 16, 2026 NCI’s Message and High Priorities May 4, 2026 Correction: A novel lncRNA SNHG29 regulates EP300- associated histone acetylation modification and inhibits FLT3-ITD AML growth Nature.com Share FacebookTwitterPinterestWhatsApp Previous articleFocusing on the glucocorticoid receptor-CCR8 axis mediated bone marrow T cell sequestration enhances infiltration of anti-tumor T cells in intracranial cancersNext articleOsteosarcoma In Youngsters: Challenges And Advances In Therapy Hot Topics Purposeful Precision Drugs: The New Precision Oncology? The Story of Immune Checkpoint Inhibitors and Immunotherapy Reflections on Progress at ASCO 2026 Load more Related Articles Editor - August 6, 2026Purposeful Precision Drugs: The New Precision Oncology? Editor - July 21, 2026The Story of Immune Checkpoint Inhibitors and Immunotherapy Editor - June 23, 2026Reflections on Progress at ASCO 2026 Load more
